Generally, low-grade papillary UC predominantly follows the FGFR3 signaling pathway, while nodular/flat UC such as carcinoma in situ and high-grade invasive disease follows the TP53 pathway [27]. The gene discussed is FGFR3; the disease is in situ carcinoma.